Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Seattle Genetics starts phase I/II trial of vadastuximab talirine in MDS

Feb. 23, 2016

OBI Pharma reports topline results for OBI-822/821 in patients with metastatic breast cancer

Feb. 23, 2016

Phase II trial explores use of glembatumumab vedotin in recurrent or refractory osteosarcoma

Feb. 23, 2016

Apogenix receives grant for immuno-oncology candidate and companion diagnostic

Feb. 17, 2016

FDA grants breakthrough therapy designation for durvalumab

Feb. 17, 2016

European approval for Portrazza for advanced squamous NSCLC

Feb. 16, 2016

PDS Biotechnology and NCI to codevelop novel cancer immunotherapies

Feb. 15, 2016

Patient with B-cell lymphoma in remission following treatment with OXS-1550

Feb. 11, 2016

SymBio and Teikyo Heisei University collaborate to develop TTR1 therapeutic anticancer drug

Feb. 11, 2016

FDA lifts partial clinical hold on vesigenurtucel-L

Feb. 11, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...